Patient characteristics
| Characteristic | N (%) (N=23) |
| Age, median (range) | 36 (23–70) |
| Male | 15 (65) |
| Race | |
| White | 19 (83) |
| Black/African American | 3 (13) |
| Other | 1 (4) |
| Baseline KPS, median (range) | 90 (80–100) |
| Diagnosis | |
| Gray zone lymphoma | 1 (4) |
| Hodgkin’s lymphoma | 20 (87) |
| T-cell lymphoma | 2 (9) |
| Stage at diagnosis | |
| I | 2 (9) |
| II | 6 (26) |
| III | 9 (39) |
| IV | 6 (26) |
| Number of prior therapies, median (range) | 7 (3–12) |
| Prior BV | 22 (96) |
| Prior checkpoint inhibitor | 16 (70) |
| Prior AutoSCT | 17 (74) |
| Prior AlloSCT | 10 (43) |
| Active disease at treatment | 17 (74) |
| Dose level | |
| 1×108 cells/m2 | 3 (13) |
| 2×108 cells/m2 | 20 (87) |
| Lymphodepletion type | |
| Bendamustine | 7 (30) |
| Fludarabine/bendamustine | 16 (70) |
| CRS status | |
| Grade 1 CRS | 4 (17) |
| Grade 2 CRS | 1 (4) |
| No CRS | 18 (78) |
| Response to CAR-T | |
| Responder (CR, PR) | 16 (70) |
| Non-responder (SD, PD) | 7 (30) |
AlloSCT, allogeneic stem cell transplant; AutoSCT, autologous stem cell transplant; BV, brentuxumab vedotin; CR, complete response; CRS, cytokine release syndrome; KPS, Karnofsky Performance Status; PD, progressive disease; PR, partial response; SD, stable disease.